Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Setting up an autonomic unit within the neurological department: a position statement of the European Federation of Autonomic Societies.

Clinical autonomic research : official journal of the Clinical Autonomic Research Society·2026
Same author

Postural orthostatic tachycardia syndrome is the most frequent cardiovascular autonomic disorder following COVID-19 infection or vaccination.

Journal of neurology·2025
Same author

MeDeMSA care study protocol: developing personalized best medical care with integrated mobile palliative and telemedicine support for individuals with multiple system atrophy.

Journal of neural transmission (Vienna, Austria : 1996)·2025
Same author

Transcriptional dysregulation in the cerebellum triggered by oligodendroglial α-synucleinopathy: insights from a transgenic mouse into the early disease mechanisms of MSA.

Journal of neural transmission (Vienna, Austria : 1996)·2025
Same author

Multiple system atrophy: advances in pathophysiology, diagnosis, and treatment.

The Lancet. Neurology·2024
Same author

Long-Term Medication Profiles in Parkinson's Disease under Subthalamic Deep Brain Stimulation: A Controlled Study.

Movement disorders clinical practice·2024
Same journal

AQP4 and MOG Characterize the Autoantibody Landscape of Checkpoint Blockade-Induced Optic Neuritis.

Annals of neurology·2026
Same journal

Five Issues of Artificial Intelligence in Science: Sailing the Ship of Theseus.

Annals of neurology·2026
Same journal

Reply to "Clinical Value of Aneurysm Wall Enhancement in Unruptured Intracranial Aneurysm".

Annals of neurology·2026
Same journal

Clinical Value of Aneurysm Wall Enhancement in Unruptured Intracranial Aneurysm.

Annals of neurology·2026
Same journal

Imaging of Neurovascular Compression in Thoracic Outlet Syndrome.

Annals of neurology·2026
Same journal

Reply to "Methodological Challenges in Interpreting SAA-Defined Imaging Subgroups in Parkinson's Disease".

Annals of neurology·2026
See all related articles

Related Experiment Video

Updated: Jun 29, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Multiple system atrophy: a primary oligodendrogliopathy.

Gregor K Wenning1, Nadia Stefanova, Kurt A Jellinger

  • 1Department of Neurology, Innsbruck Medical University, Innsbruck, Austria. gregor.wenning@i-med.ac.at

Annals of Neurology
|October 1, 2008
PubMed
Summary
This summary is machine-generated.

Multiple system atrophy (MSA) is a neurodegenerative disease with unknown causes. Research suggests MSA may be a primary glial disorder involving myelin disruption, sharing similarities with demyelinating diseases.

More Related Videos

Generation of Oligodendrocytes and Oligodendrocyte-Conditioned Medium for Co-Culture Experiments
09:05

Generation of Oligodendrocytes and Oligodendrocyte-Conditioned Medium for Co-Culture Experiments

Published on: February 9, 2020

Related Experiment Videos

Last Updated: Jun 29, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Generation of Oligodendrocytes and Oligodendrocyte-Conditioned Medium for Co-Culture Experiments
09:05

Generation of Oligodendrocytes and Oligodendrocyte-Conditioned Medium for Co-Culture Experiments

Published on: February 9, 2020

Area of Science:

  • Neuroscience
  • Neuropathology

Background:

  • Multiple system atrophy (MSA) pathogenesis remains largely unknown, despite extensive research.
  • MSA is clinically and pathologically linked to Parkinson's disease and cerebellar degeneration.
  • Advances include identifying oligodendrocytes as the cellular target and alpha-synuclein inclusions as a marker.

Purpose of the Study:

  • To review the evolving understanding of MSA's underlying cause.
  • To explore the potential link between MSA and demyelinating disorders.
  • To highlight recent findings strengthening the glial disorder model of MSA.

Main Methods:

  • Literature review of clinical, morphological, and biochemical studies on MSA.
  • Analysis of research on alpha-synuclein, oligodendrocytes, myelin basic protein, and p25alpha (TPPP).
  • Comparison of MSA phenotypes with Parkinson's disease and demyelinating disorders.

Main Results:

  • MSA involves oligodendrocytes, with dysregulation in myelin basic protein and p25alpha metabolism observed.
  • These oligodendrocytic changes may precede glial cytoplasmic inclusion formation in early MSA.
  • MSA shares characteristics with demyelinating disorders, primarily myelin disruption leading to axonal dysfunction.

Conclusions:

  • MSA may share pathological traits with demyelinating disorders, suggesting a primary oligodendrogliopathy.
  • Myelin disruption is a common feature, potentially leading to secondary axonal damage.
  • Further research into glial dysfunction is crucial for understanding MSA etiology.